Long-read sequencing to resolve the missing heritability in patients suspected o...
Long-read sequencing to resolve the missing heritability in patients suspected of PTEN hamartoma tumour syndrome
Individuals with a genetic tumour risk syndrome are at high risk to develop cancer. One of these syndromes is PTEN hamartoma tumour syndrome (PHTS). PHTS is associated with pathogenic variants (PVs) in the PTEN gene. Unfortunately...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SAF2017-89116-R
MALFORMATIONES VASCULARES ONCOGENICAS DESDE LA BIOLOGIA HAST...
242K€
Cerrado
OR-HMC
Assay for cancer diagnostics by quantification of 5hmC
150K€
Cerrado
SAF2016-80157-R
MECANISMOS MOLECULARES DE PROGRESION TUMORAL EN MODELOS DE N...
157K€
Cerrado
EpiCblood
Towards early cancer detection and tumor classification usin...
1M€
Cerrado
EpiCancer
Comprehensive Platform for the Functional Characterization o...
2M€
Cerrado
EQC2018-004733-P
ADQUISIÓN DE EQUIPO PARA IDENTIFICACIÓN Y RECUPERACIÓN DE CÉ...
171K€
Cerrado
Información proyecto RESEMBLE
Duración del proyecto: 24 meses
Fecha Inicio: 2022-04-28
Fecha Fin: 2024-05-14
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Individuals with a genetic tumour risk syndrome are at high risk to develop cancer. One of these syndromes is PTEN hamartoma tumour syndrome (PHTS). PHTS is associated with pathogenic variants (PVs) in the PTEN gene. Unfortunately, in the majority of patients suspected of PHTS no PV in PTEN is identified. These patients are considered PHTS-like. The low diagnosis rate in this group of patients suggests the possibility of PVs in regions of PTEN that are not covered in routine diagnostics or suggests that PVs in other genes in the PI3K/AKT/mTOR pathway result in PHTS-like disease. In order to identify the missing heritability in PHTS I aim to develop a long-read sequencing (LRS) approach for PHTS-like patients, which will go beyond the currently state-of-the-art short-read sequencing approaches. I will O1) develop a PTEN-targeted LRS assay and O2) perform this assay on a highly selective cohort of PHTS-like families (n=94). I then will O3) perform whole genome LRS on 25 families that were not solved by targeted LRS to identify novel gene-disease associations. At last, I will O4) validate these new associations in a wider cohort.
Via this work, I will improve the diagnostic yield for PHTS by identifying novel genetic mechanisms and genes underlying disease in PHTS-like patients. The unique interdisciplinary structure of the Department of Human Genetics at Radboudumc will allow to rapidly implement genetic testing for the newly identified genetic causes for PHTS. Identification of the precise underlying cause of PHTS will enable cascade genetic testing of at-risk family members to determine their status for the causal variant and thus, risk of disease to them and any future off-spring. Furthermore, this approach will allow the implementation of preventive care strategies for the family members at risk. Overall, my proposal will facilitate a personalized care approach for PHTS(-like) patients and their families for improved clinical outcomes and reduced disease morbidity